Provided by Tiger Trade Technology Pte. Ltd.

Merck

152.55
+3.562.39%
Pre-market: 153.230.6800+0.45%06:04 EDT
Volume:15.98M
Turnover:2.44B
Market Cap:376.37B
PE:119.85
High:154.49
Open:149.12
Low:148.59
Close:148.99
52wk High:154.49
52wk Low:77.58
Shares:2.47B
Float Shares:2.47B
Volume Ratio:1.07
T/O Rate:0.65%
Dividend:3.32
Dividend Rate:2.18%
EPS(TTM):1.27
EPS(LYR):7.28
ROE:6.96%
ROA:11.87%
PB:8.98
PE(LYR):20.95

Loading ...

Phanes Therapeutics: Expansion of Clinical Trial Collaboration and Supply Agreement with Merck

THOMSON REUTERS
·
Jul 21

Stocks Need Some Tech Magic to Kickstart Market Rally

Dow Jones
·
Jul 20

Palantir Stock Price Still Misses Its Cash Flow Strength

Simply Wall St.
·
Jul 20

Personalis Has Already Doubled—Is Merck About To Trigger Another Surge?

Smartkarma
·
Jul 20

What Comes After Merck's Keytruda? the Race for the Next Standard Cancer Treatment.

Dow Jones
·
Jul 20

Merck Animal Health Division's Inactivated Intradermal Immunization Vaccine for Porcine Mycoplasma Pneumonia Approved in China - Company Notice

THOMSON REUTERS
·
Jul 20

Movement Alert|Merck Rises 3.09% in Regular Trading, Oral PCSK9 Inhibitor Lipfendra Receives FDA Approval

Market Focus
·
Jul 17

July 2026's Top Stock Selections Estimated Below Fair Market Value

Simply Wall St.
·
Jul 17

Sector Update: Healthcare

MT Newswires Live
·
Jul 17

Merck's HIV Pipeline Nears Key Inflection Point Ahead of ISLEND Data, RBC Says

MT Newswires Live
·
Jul 16

Unitedhealth, Merck Share Gains Contribute to Dow's 166-point Jump

Dow Jones
·
Jul 16

Merck & Co Inc Stock (MRK) Moved Up by 3.24% on Jul 16: Drivers Behind the Movement

TradingKey
·
Jul 16

Merck (MRK) Rises after FDA Clears First Oral PCSK9 Cholesterol Pill

TIPRANKS
·
Jul 16

Movement Alert|Merck Rises 3.09% in Regular Trading, Oral PCSK9 Inhibitor Lipfendra Wins FDA Approval

Market Focus
·
Jul 16

Merck Gets US FDA Nod for First-in-its-class Oral Cholesterol Drug

Reuters
·
Jul 16

Merck & Co Inc: List Price (wholesale Acquisition Cost) for Lipfendra Will be $10.50 Per Day, Based on a 30-day Supply

THOMSON REUTERS
·
Jul 16

Merck’s Lipfendra approved by FDA for adults with hypercholesterolemia

TIPRANKS
·
Jul 16

Merck Says FDA Approves Oral PCSK9 Inhibitor Lipfendra for Adults with High LDL-C

Reuters
·
Jul 16

Merck’s Lipfendra® (enlicitide) is the First and Only Once-daily Oral Pcsk9 Inhibitor Approved by the U.S. FDA to Reduce Ldl-c in Adults with Hypercholesterolemia

THOMSON REUTERS
·
Jul 16

Merck: FDA Approves Lipfendra Tablets 20 Mg to Reduce Low-density Lipoprotein Cholesterol in Adults with Hypercholesterolemia

THOMSON REUTERS
·
Jul 16